Drugs / AFACIFENACIN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00409539 | Dec 2006 → Jun 2008 | overactive bladder | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-03-07 | Sumitomo Pharma America, Inc. | Dainippon Sumitomo Pharma and Nippon Shinyaku conclude a license agreement for SMP-986, a therapeutic agent for urology sumitomo-pharma.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFACIFENACIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545165 ↗ |
| Known as | Afacifenacina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545165 ↗ |
| Known as | Afacifenacine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545165 ↗ |
| Known as | NS-986 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545165 ↗ |
| Known as | SMP-986 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00409539 ↗ |
| Action | Inhibit | “Sodium channel protein type XI alpha subunit blocker” CHEMBL3545165 ↗1“Sodium channel protein type X alpha subunit blocker” CHEMBL3545165 ↗ |
| Modality | Small molecule | — CHEMBL3545165 ↗ |
| Target | SCN10A | “Sodium channel protein type X alpha subunit blocker” CHEMBL3545165 ↗ |
| Target | SCN11A | “Sodium channel protein type XI alpha subunit blocker” CHEMBL3545165 ↗ |